Tandem Diabetes Care, Inc. announced the publication of a study titled "Adults with Type 2 Diabetes Benefit from Automated Insulin Delivery Irrespective of C-peptide Level" in the American Diabetes Association’s Diabetes Care. This sub-analysis from the 2IQP randomized, controlled trial found that the Control-IQ+ automated insulin delivery (AID) system was beneficial for adults with insulin-treated type 2 diabetes, regardless of their C-peptide levels. The study included 254 participants from the 2IQP trial.
Participants using the AID system experienced a mean HbA1c decrease of 0.8% from baseline, an improvement that was consistent across both high and low C-peptide groups. This finding indicates that the benefits of AID are present irrespective of C-peptide levels. The study highlights a discrepancy with current CMS criteria, which often require a low C-peptide level for insulin pump coverage, potentially excluding many type 2 diabetes patients from accessing AID systems.
The publication reinforces the clinical effectiveness of Control-IQ+ technology for a broad population of type 2 diabetes patients. It provides further evidence to support broader reimbursement policies that do not restrict access based on C-peptide levels, potentially expanding the market for Tandem's AID systems.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.